Extracellular vesicles have emerged as prominent regulators of the immune response during tumor progression. EVs contain a diverse repertoire of molecular cargo that plays a critical role in immunomodulation. Here, we identify the role of EVs as mediators of communication between cancer and immune cells. This expanded role of EVs may shed light on the mechanisms behind tumor progression and provide translational diagnostic and prognostic tools for immunologists.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors
Nature Communications Open Access 14 July 2022
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy
Molecular Cancer Open Access 14 January 2022
Cell Communication and Signaling Open Access 16 October 2021
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Yáñez-mó, M. et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 4, 27066 (2015).
Colombo, M., Raposo, G. & Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014).
Kalra, H., Drummen, G. P. C. & Mathivanan, S. Focus on extracellular vesicles: Introducing the next small big thing. Int. J. Mol. Sci. 17, 170 (2016).
Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200, 373–383 (2013).
Théry, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750 (2018).
Niel, G. Van, Angelo, G. D. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228 (2018).
Xu, R. et al. Extracellular vesicles in cancer—implications for future improvements in cancer care. Nat. Rev. Clin. Oncol. 15, 617–638 (2018).
Becker, A. et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 30, 836–848 (2016).
Raposo, G. et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183, 1161–1172 (1996).
Zitvogel, L. et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4, 594–600 (1998).
Théry, C. et al. Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol. 3, 1156–1162 (2002).
Mallegol, J. et al. T84-intestinal epithelial exosomes bear MHC class II/peptide complexes potentiating antigen presentation by dendritic cells. Gastroenterology 132, 1866–1876 (2007).
Admyre, C. et al. Exosomes with major histocompatibility complex class II and co-stimulatory molecules are present in human BAL fluid. Eur. Respir. J. 22, 578–583 (2003).
Utsugi-Kobukai, S., Fujimaki, H., Hotta, C., Nakazawa, M. & Minami, M. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol. Lett. 89, 125–131 (2003).
Clayton, A. et al. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J. Immunol. Methods 247, 163–174 (2001).
Lynch, S. et al. Novel MHC class I structures on exosomes. J. Immunol. 183, 1884–1891 (2009).
Bobrie, A., Colombo, M., Raposo, G. & Théry, C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 12, 1659–1668 (2011).
Hwang, I., Shen, X. & Sprent, J. Direct stimulation of naïve T cells by membrane vesicles from antigen-presenting cells: Distinct roles for CD54 and B7 molecules. Proc. Natl Acad. Sci. USA 100, 6670–6675 (2003).
Alexander, M. et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat. Cell Biol. 6, 7321 (2015).
Admyre, C., Johansson, S. M., Paulie, S. & Gabrielsson, S. Direct exosome stimulation of peripheral human T cells detected by ELISPOT. Eur. J. Immunol. 36, 1772–1781 (2006).
Fitzgerald, W. et al. A system of cytokines encapsulated in extracellular vesicles. Sci. Rep. 8, 8973 (2018).
Qazi, K. R., Gehrmann, U., Jordo, E. D., Karlsson, M. C. I. & Gabrielsson, S. Antigen-loaded exosomes alone induce TH1-type memory through a B cell–dependent mechanism. Immunobiology 113, 2673–2683 (2009).
Tkach, M. et al. Qualitative differences in T‐cell activation by dendritic cell‐derived extracellular vesicle subtypes. EMBO J. 36, 3012–3028 (2017).
Vincent-Schneider, H. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int. Immunol. 14, 713–722 (2002).
Ruhland, M. K. et al. Visualizing synaptic transfer of tumor antigens among dendritic cells. Cancer Cell 37, 786–799.e5 (2020).
Alvarez-Jiménez, V. D. et al. Extracellular vesicles released from mycobacterium tuberculosis-infected neutrophils promote macrophage autophagy and decrease intracellular mycobacterial survival. Front. Immunol. 9, 272 (2018).
Danesh, A. et al. Granulocyte-derived extracellular vesicles activate monocytes and are associated with mortality in intensive care unit patients. Front. Immunol. 9, 956 (2018).
Xu, Y. et al. Macrophages transfer antigens to dendritic cells by releasing exosomes containing dead-cell-associated antigens partially through a ceramide-dependent pathway to enhance CD4+ T-cell responses. Immunology 149, 157–171 (2016).
Becker, P. D. et al. B lymphocytes contribute to indirect pathway T cell sensitisation via acquisition of extracellular vesicles. Am. J. Transplant. https://doi.org/10.1111/ajt.16088 (2020).
Zeng, F. & Morelli, A. E. Extracellular vesicle-mediated MHC cross-dressing in immune homeostasis, transplantation, infectious diseases, and cancer. Semin. Immunopathol. 40, 477–490 (2018).
Huang, L. et al. Exosomes from thymic stromal lymphopoietin-activated dendritic cells promote Th2 differentiation through the OX40 ligand. Pathobiology 86, 111–117 (2019).
Kremer, A. N. et al. Natural T-cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles. Eur. J. Immunol. 48, 1621–1631 (2018).
Wei, G. et al. Dendritic cells derived exosomes migration to spleen and induction of inflammation are regulated by CCR7. Sci. Rep. 7, 42996 (2017).
Schierer, S. et al. Extracellular vesicles from mature dendritic cells (DC) differentiate monocytes into immature DC. Life Sci. Alliance 1, e201800093 (2018).
Kowal, J. et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc. Natl Acad. Sci. USA 113, E968–E977 (2016).
Cui, X. et al. Thyrocyte-derived exosome-targeted dendritic cells stimulate strong CD4+ T lymphocyte responses. Mol. Cell. Endocrinol. 506, 110756 (2020).
Cai, Z. et al. Immunosuppressive exosomes from TGF-$β$1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. Cell Res. 22, 607–610 (2012).
Zhang, M. et al. Inhibition of MicroRNA let-7 depresses maturation and functional state of dendritic cells in response to lipopolysaccharide stimulation via targeting suppressor of cytokine signaling 1. J. Immunol. 187, 1674–1683 (2011).
Lindenbergh, M. F. S. et al. Bystander T-cells support clonal T-cell activation by controlling the release of dendritic cell-derived immune-stimulatory extracellular vesicles. Front. Immunol. 10, 448 (2019).
Torralba, D. et al. Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven contacts. Nat. Commun. 9, 2658 (2018).
Chiou, N. et al. Selective export into extracellular vesicles and function of tRNA fragments during T cell activation. Cell Rep. 25, 3356–3370.e4 (2018).
Segura, E., Amigorena, S. & The, C. Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells, Mol. Dis. 35, 89–93 (2005).
Kaur, S. et al. CD63, MHC class 1, and CD47 identify subsets of extracellular vesicles containing distinct populations of noncoding RNAs. Sci. Rep. 8, 2577 (2018).
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). J. Immunol. 155, 1151–1165 (1995).
Tung, S. L. et al. Regulatory T cell-derived extracellular vesicles modify dendritic cell function. Sci. Rep. 8, 6065 (2018).
Tung, S. L. et al. Regulatory T cell extracellular vesicles modify T-effector cell cytokine production and protect against human skin allograft damage. Front. Cell Dev. Biol. 8, 317 (2020).
Aiello, S. et al. Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. Sci. Rep. 7, 11518 (2017).
Okoye, I. S. et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity 41, 89–103 (2014).
Torri, A. et al. Extracellular MicroRNA signature of human helper T cell subsets in health and autoimmunity. J. Biol. Chem. 292, 2903–2915 (2017).
Chen, L. et al. Exosomes derived from T regulatory cells suppress CD8+ cytotoxic T lymphocyte proliferation and prolong liver allograft survival. Med. Sci. Monit. 25, 4877–4884 (2019).
Naqvi, A. R., Fordham, J. B., Ganesh, B. & Nares, S. MiR-24, miR-30b and miR-142-3p interfere with antigen processing and presentation by primary macrophages and dendritic cells. Sci. Rep. 6, 1–12 (2016).
Sullivan, J. A. et al. Treg-cell-derived IL-35-coated extracellular vesicles promote infectious tolerance. Cell Rep. 30, 1039–1051.e5 (2020).
Turnis, M. E. et al. Interleukin-35 limits anti-tumor immunity. Immunity 44, 316–329 (2016).
Kim, S. H., Bianco, N. R., Shufesky, W. J., Morelli, A. E. & Robbins, P. D. MHC class II+ exosomes in plasma suppress inflammation in an antigen-specific and fas ligand/fas-dependent manner. J. Immunol. 179, 2235–2241 (2007).
Kim, S. H. et al. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol. Ther. 13, 289–300 (2006).
O Reilly, L. A. et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 461, 659–663 (2009).
Monleón, I. et al. Differential secretion of fas ligand- or APO2 Ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J. Immunol. 167, 6736–6744 (2001).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Hiratsuka, S., Watanabe, A., Aburatani, H. & Maru, Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8, 1369–1375 (2006).
Oskarsson, T. et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 17, 867–874 (2011).
Kano, A. Tumor cell secretion of soluble factor(s) for specific immunosuppression. Sci. Rep. 5, 8913 (2015).
Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329 (2015).
Muller, L., Mitsuhashi, M., Simms, P., Gooding, W. E. & Whiteside, T. L. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci. Rep. 6, 20254 (2016).
Clayton, A. & Tabi, Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells, Mol. Dis. 34, 206–213 (2005).
Capello, M. et al. Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat. Commun. 10, 254 (2019).
Mahaweni, N. M., Kaijen-Lambers, M. E. H., Dekkers, J., Aerts, J. G. J. V. & Hegmans, J. P. J. J. Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma. J. Extracell. Vesicles 2, 22492 (2013).
Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012).
Costa-Silva, B. et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015).
Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382–386 (2018).
Czystowska-Kuzmicz, M. et al. Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat. Commun. 10, 3000 (2019).
Ricklefs, F. L. et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci. Adv. 4, eaar2766 (2018).
Haderk, F. et al. Tumor-derived exosomes modulate PD-L1 expression in monocytes. Sci. Immunol. 2, 28 (2017).
Karwacz, K. et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol. Med. 3, 581–592 (2011).
Daassi, D., Mahoney, K. M. & Freeman, G. J. The importance of exosomal PDL1 in tumour immune evasion. Nat. Rev. Immunol. 20, 209–215 (2020).
Vignard, V. et al. MicroRNAs in tumor exosomes drive immune escape in melanoma. Cancer Immunol. Res. 8, 255–267 (2020).
Rodriguez, P. C. et al. Regulation of T cell receptor CD3ζ chain expression byl-Arginine. J. Biol. Chem. 277, 21123–21129 (2002).
Van De Velde, L. A. et al. T cells encountering myeloid cells rogrammed for amino acid-dependent immunosuppression use Rictor/mTORC2 protein for proliferative checkpoint decisions. J. Biol. Chem. 292, 15–30 (2017).
Rodriguez, P. C., Quiceno, D. G. & Ochoa, A. C. l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109, 1568–1573 (2006).
Salimu, J. et al. Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes. J. Extracell. Vesicles 6, 1368823 (2017).
Hsu, Y. L. et al. Hypoxic lung-cancer-derived extracellular vesicle microRNA-103a increases the oncogenic effects of macrophages by targeting PTEN. Mol. Ther. 26, 568–581 (2018).
de Jong, O. G. et al. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. J. Extracell. Vesicles 1, https://doi.org/10.3402/jev.v1i0.18396 (2012).
Park, J. E. et al. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene 38, 5158–5173 (2019).
Lenzini, S., Bargi, R., Chung, G. & Shin, J.-W. Matrix mechanics and water permeation regulate extracellular vesicle transport. Nat. Nanotechnol. 15, 217–223 (2020).
Gilkes, D. M., Semenza, G. L. & Wirtz, D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 14, 430–439 (2014).
Diaz, B. & Yuen, A. The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia 2, 91 (2014).
Berchem, G. et al. Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer. Oncoimmunology 5, e1062968 (2016).
Kim, D.-H. & Wirtz, D. Cytoskeletal tension induces the polarized architecture of the nucleus. Biomaterials 48, 161–172 (2015).
Fraley, S. I., Feng, Y., Giri, A., Longmore, G. D. & Wirtz, D. Dimensional and temporal controls of three-dimensional cell migration by zyxin and binding partners. Nat. Commun. 3, 719 (2012).
Khatau, S. B. et al. A perinuclear actin cap regulates nuclear shape. Proc. Natl Acad. Sci. 106, 19017–19022 (2009).
Wirtz, D., Konstantopoulos, K. & Searson, P. C. The physics of cancer: The role of physical interactions and mechanical forces in metastasis. Nat. Rev. Cancer 11, 512–522 (2011).
Follain, G. et al. Fluids and their mechanics in tumour transit: shaping metastasis. Nat. Rev. Cancer 20, 107–124 (2020).
Dionisi, M. et al. Tumor-derived microvesicles enhance cross-processing ability of clinical grade dendritic cells. Front. Immunol. 9, 2481 (2018).
Huang, F., Wan, J., Hu, W. & Hao, S. Enhancement of anti-leukemia immunity by leukemia-derived exosomes via downregulation of TGF-β1 expression. Cell. Physiol. Biochem. 44, 240–254 (2017).
Rughetti, A. et al. Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing. Cancer Immunol. Res. 2, 177–186 (2014).
Kitai, Y. et al. DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J. Immunol. 198, 1649–1659 (2017).
Lin, W. et al. Radiation-induced small extracellular vesicles as ‘carriages’ promote tumor antigen release and trigger antitumor immunity. Theranostics 10, 4871–4884 (2020).
Squadrito, M. L., Cianciaruso, C., Hansen, S. K. & De Palma, M. EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat. Methods 15, 183–186 (2018).
Zhang, H. et al. Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS/STING signaling. Cancer Immunol. Res. 3, 196–205 (2015).
Caruso Bavisotto, C. et al. Immunomorphological pattern of molecular chaperones in normal and pathological thyroid tissues and circulating exosomes: Potential use in clinics. Int. J. Mol. Sci. 20, 4496 (2019).
Diamond, J. M. et al. Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs. Cancer Immunol. Res. 6, 910–920 (2018).
Ma, J. et al. Mechanisms by which dendritic cells present tumor microparticle antigens to CD8+ T cells. Cancer Immunol. Res. 6, 1057–1069 (2018).
Jeppesen, D. K. et al. Reassessment of exosome composition. Cell 177, 428–445.e18 (2019).
Menay, F. et al. Exosomes isolated from ascites of T-cell lymphoma-bearing mice expressing surface CD24 and HSP-90 induce a tumor-specific immune response. Front. Immunol. 8, 286 (2017).
Daßler-Plenker, J. et al. RIG-I activation induces the release of extracellular vesicles with antitumor activity. Oncoimmunology 5, e1219827 (2016).
Gastpar, R. et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 65, 5238–5247 (2005).
Li, Q. et al. Bifacial effects of engineering tumour cell-derived exosomes on human natural killer cells. Exp. Cell. Res. 363, 141–150 (2018).
Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J. & Chen, W. Exosomes and their roles in immune regulation and cancer. Semin. Cell Developmental Biol. 40, 72–81 (2015).
Scholl, J. N. et al. Characterization and antiproliferative activity of glioma-derived extracellular vesicles. Nanomedicine 15, 1001–1018 (2020).
Salamon, P., Mekori, Y. A. & Shefler, I. Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironment. Cancer Immunol. Immunother. 69, 373–381 (2020).
Pucci, F. et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle–B cell interactions. Science 352, 242–246 (2016).
Seo, N. et al. Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells. Nat. Commun. 9, 435 (2018).
Peters, P. J. et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J. Exp. Med. 173, 1099–1109 (1991).
Lu, Z. et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J. Hepatol. 67, 739–748 (2017).
Ostheimer, C., Gunther, S., Bache, M., Vordermark, D. & Multhoff, G. Dynamics of heat shock protein 70 serum levels as a predictor of clinical response in non-small-cell lung cancer and correlation with the hypoxia-related marker osteopontin. Front. Immunol. 8, 1305 (2017).
Gao, Y. et al. Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines. Oncol. Rep. 36, 1243–1250 (2016).
Blachere, B. N. E. et al. Heat shock protein—peptide complexes, reconstituted in. J. Exp. Med. 186, 1315–1322 (1997).
Ochyl, L. J. et al. PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy. Biomaterials 182, 157–166 (2018).
Koh, E. et al. Exosome–SIRPα, a CD47 blockade increases cancer cell phagocytosis. Biomaterials 121, 121–129 (2017).
Kamerkar, S. et al. Therapeutic targeting of oncogenic KRAS in pancreatic cancer by engineered exosomes. Nature 546, 498–503 (2017).
Rana, S., Yue, S., Stadel, D. & Zöller, M. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int. J. Biochem. Cell Biol. 44, 1574–1584 (2012).
Sun, H. et al. A multifunctional liposomal nanoplatform co-delivering hydrophobic and hydrophilic doxorubicin for complete eradication of xenografted tumors. Nanoscale 11, 17759–17772 (2019).
Watson, D. C. et al. Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials 105, 195–205 (2016).
Whitford, W. & Guterstam, P. Exosome manufacturing status. Future Med. Chem. 11, 1225–1236 (2019).
Zhao, Z., McGill, J., Gamero-Kubota, P. & He, M. Microfluidic on-demand engineering of exosomes towards cancer immunotherapy. Lab Chip 19, 1877–1886 (2019).
Luan, X. et al. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017).
Zhou, H. et al. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int. 69, 1471–1476 (2006).
Jeyaram, A. & Jay, S. M. Preservation and storage stability of extracellular vesicles for therapeutic applications. AAPS J. 20, 1–7 (2018).
Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).
Asadirad, A. et al. Phenotypical and functional evaluation of dendritic cells after exosomal delivery of miRNA-155. Life Sci. 219, 152–162 (2019).
Dusoswa, S. A. et al. Glycan modification of glioblastoma-derived extracellular vesicles enhances receptor-mediated targeting of dendritic cells. J. Extracell. Vesicles 8, 1648995 (2019).
Gu, X., Erb, U., Büchler, M. W. & Zöller, M. Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int. J. Cancer 136, E74–E84 (2015).
Rossowska, J. et al. Antitumor potential of extracellular vesicles released by genetically modified murine colon carcinoma cells with overexpression of interleukin-12 and shRNA for TGF-β1. Front. Immunol. 10, 211 (2019).
Matsumoto, A., Takahashi, Y., Ariizumi, R., Nishikawa, M. & Takakura, Y. Development of DNA-anchored assembly of small extracellular vesicle for efficient antigen delivery to antigen presenting cells. Biomaterials 225, 119518 (2019).
Morishita, M., Takahashi, Y., Nishikawa, M., Ariizumi, R. & Takakura, Y. Enhanced class I tumor antigen presentation via cytosolic delivery of exosomal cargos by tumor-cell-derived exosomes displaying a pH-sensitive fusogenic peptide. Mol. Pharm. 14, 4079–4086 (2017).
Zuo, B. et al. Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice. Nat. Commun. 11, 1–16 (2020).
Al-Samadi, A. et al. Crosstalk between tongue carcinoma cells, extracellular vesicles, and immune cells in in vitro and in vivo models. Oncotarget 8, 60123–60134 (2017).
Morishita, M., Takahashi, Y., Matsumoto, A., Nishikawa, M. & Takakura, Y. Exosome-based tumor antigens–adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. Biomaterials 111, 55–65 (2016).
Huang, F. et al. TGF-β1-silenced leukemia cell-derived exosomes target dendritic cells to induce potent anti-leukemic immunity in a mouse model. Cancer Immunol. Immunother. 66, 1321–1331 (2017).
Guo, D. et al. Exosomes from heat-stressed tumour cells inhibit tumour growth by converting regulatory T cells to TH17 cells via IL-6. Immunology 154, 132–143 (2018).
Gobbo, J. et al. Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer. J. Natl Cancer Inst. 108, 1–11 (2016).
Bell, B. M., Kirk, I. D., Hiltbrunner, S., Gabrielsson, S. & Bultema, J. J. Designer exosomes as next-generation cancer immunotherapy. Nanomed. Nanotechnol. Biol. Med. 12, 163–169 (2016).
Pitt, J. M. et al. Dendritic cell-derived exosomes for cancer therapy. J. Clin. Invest. 126, 1224–1232 (2016).
Tran, T. H., Mattheolabakis, G., Aldawsari, H. & Amiji, M. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clin. Immunol. 160, 46–58 (2015).
Besse, B. et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology 5, e1071008 (2016).
Chen, S. et al. Poly(I:C) enhanced anti-cervical cancer immunities induced by dendritic cells-derived exosomes. Int. J. Biol. Macromol. 113, 1182–1187 (2018).
Matsumoto, A., Asuka, M., Takahashi, Y. & Takakura, Y. Antitumor immunity by small extracellular vesicles collected from activated dendritic cells through effective induction of cellular and humoral immune responses. Biomaterials 252, 120112 (2020).
Zhu, L. et al. Novel alternatives to extracellular vesicle-based immunotherapy–exosome mimetics derived from natural killer cells. Artif. Cells, Nanomed. Biotechnol. 46, S166–S179 (2018).
Zhu, L. et al. Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics 7, 2732–2745 (2017).
Zhu, L. et al. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming. Biomaterials 190–191, 38–50 (2019).
Lee, H., Park, H., Noh, G. J. & Lee, E. S. pH-responsive hyaluronate-anchored extracellular vesicles to promote tumor-targeted drug delivery. Carbohydr. Polym. 202, 323–333 (2018).
Meng, X. et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Adv. Exp. Med. Biol. 924, 3–8 (2016).
Maji, S. et al. Exosomal annexin II promotes angiogenesis and breast cancer metastasis. Mol. Cancer Res. 15, 93–105 (2017).
Muller, L. et al. Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology 4, e1008347 (2015).
Ciravolo, V. et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J. Cell. Physiol. 227, 658–667 (2012).
Battke, C. et al. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol. Immunother. 60, 639–648 (2011).
Cordonnier, M. et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J. Extracell. Vesicles 9, 1710899 (2020).
This work was supported through grants from the National Institutes of Health (T32GM008764) to C.M. and the National Cancer Institute (U54CA143868) and the National Institute on Aging (U01AG060903) to D.W. Figures designed with BioRender.com.
The authors declare no competing interests.
Peer review information Zoltan Fehervari was the primary editor(s) on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Marar, C., Starich, B. & Wirtz, D. Extracellular vesicles in immunomodulation and tumor progression. Nat Immunol 22, 560–570 (2021). https://doi.org/10.1038/s41590-021-00899-0
This article is cited by
Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy
Molecular Cancer (2022)
Nature Reviews Immunology (2022)
NFκB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment
Journal of Pharmaceutical Investigation (2022)
Emerging Concepts on the Role of Extracellular Vesicles and Its Cargo Contents in Glioblastoma-Microglial Crosstalk
Molecular Neurobiology (2022)